Voya Investment Management LLC lifted its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 177.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,227,357 shares of the company's stock after purchasing an additional 784,974 shares during the quarter. Voya Investment Management LLC owned 0.25% of Elanco Animal Health worth $27,481,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of ELAN. Sapient Capital LLC boosted its stake in Elanco Animal Health by 0.3% during the second quarter. Sapient Capital LLC now owns 128,573 shares of the company's stock worth $3,164,000 after buying an additional 420 shares in the last quarter. Ritholtz Wealth Management raised its stake in shares of Elanco Animal Health by 5.0% in the 3rd quarter. Ritholtz Wealth Management now owns 9,335 shares of the company's stock valued at $209,000 after buying an additional 446 shares in the last quarter. Covestor Ltd raised its stake in shares of Elanco Animal Health by 48.2% in the 3rd quarter. Covestor Ltd now owns 1,383 shares of the company's stock valued at $31,000 after buying an additional 450 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Elanco Animal Health by 12.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,184 shares of the company's stock valued at $94,000 after buying an additional 464 shares in the last quarter. Finally, North Dakota State Investment Board lifted its holdings in shares of Elanco Animal Health by 3.4% during the 3rd quarter. North Dakota State Investment Board now owns 15,132 shares of the company's stock worth $339,000 after acquiring an additional 496 shares during the period. 97.48% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on ELAN shares. KeyCorp reiterated an "overweight" rating on shares of Elanco Animal Health in a research report on Monday, November 9th. UBS Group increased their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. The Goldman Sachs Group began coverage on shares of Elanco Animal Health in a research note on Friday, October 16th. They set a "buy" rating and a $32.00 price target for the company. Morgan Stanley cut their price target on shares of Elanco Animal Health from $26.00 to $25.00 and set an "equal weight" rating for the company in a research note on Thursday, October 29th. Finally, Jefferies Financial Group downgraded Elanco Animal Health from a "buy" rating to a "hold" rating and decreased their price objective for the company from $31.00 to $24.00 in a report on Tuesday, October 20th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $30.36.
View Our Latest Report on ELAN
Elanco Animal Health Stock Down 1.9%
Shares of NYSE:ELAN opened at $25.78 on Friday. Elanco Animal Health Incorporated has a 52 week low of $19.40 and a 52 week high of $27.98. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.07 and a current ratio of 2.09. The company's fifty day moving average is $23.64 and its 200-day moving average is $23.92. The company has a market capitalization of $12.89 billion, a PE ratio of -85.93, a P/E/G ratio of 2.23 and a beta of 1.73.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.07. The business had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. The firm's quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 1.18 earnings per share for the current fiscal year.
Elanco Animal Health declared that its board has initiated a share repurchase plan on Thursday, November 19th that permits the company to repurchase $600 million in outstanding shares. This repurchase authorization permits the company to purchase up to 4.5% of its shares through open market purchases. Stock repurchase plans are often an indication that the company's board of directors believes its stock is undervalued.
Insider Buying and Selling
In other Elanco Animal Health news, insider Timothy Bettington sold 4,350 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the sale, the insider directly owned 138,911 shares of the company's stock, valued at approximately $3,194,953. This represents a 3.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.14% of the stock is currently owned by company insiders.
Trending Headlines about Elanco Animal Health
Here are a few of the latest headlines about ELAN:
- Positive Sentiment: Elanco authorized its first share repurchase program, allowing it to buy back up to $600 million of stock—up to 4.5% of shares outstanding. The company cited stronger cash generation, balance-sheet improvement and confidence in continued business momentum. Buybacks can support earnings per share and signal management confidence. Elanco Announces Inaugural $600 Million Share Repurchase Authorization
- Positive Sentiment: Barclays raised its price target to $32 from $30 and maintained an “overweight” rating, signaling a more optimistic view of the shares. Barclays stock recommendations
Elanco Animal Health Company Profile
(
Free Report)
Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elanco Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.
While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.